APA (7th ed.) Citation

MT, G., VR, G., PC, D., C, M., EM, N., CR, M., . . . KZ, A. (2024). Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): A randomised, double-blind, placebo controlled, phase 1-2 trial. The Lancet. Haematology, 11(5), e345. https://doi.org/10.1016/S2352-3026(24)00045-0

Chicago Style (17th ed.) Citation

MT, Gladwin, et al. "Riociguat in Patients with Sickle Cell Disease and Hypertension or Proteinuria (STERIO-SCD): A Randomised, Double-blind, Placebo Controlled, Phase 1-2 Trial." The Lancet. Haematology 11, no. 5 (2024): e345. https://doi.org/10.1016/S2352-3026(24)00045-0.

MLA (9th ed.) Citation

MT, Gladwin, et al. "Riociguat in Patients with Sickle Cell Disease and Hypertension or Proteinuria (STERIO-SCD): A Randomised, Double-blind, Placebo Controlled, Phase 1-2 Trial." The Lancet. Haematology, vol. 11, no. 5, 2024, p. e345, https://doi.org/10.1016/S2352-3026(24)00045-0.